Find and Replace: R&D Investment Following the Erosion of Existing Products

• 成果类型: Article
• 署名作者: Krieger, Joshua L.; Li, Xuelin; Thakor, Richard T.
• 署名单位: Harvard University; University of South Carolina System; University of South Carolina Columbia; University of Minnesota System; University of Minnesota Twin Cities; Massachusetts Institute of Technology (MIT)
• 刊物名称: MANAGEMENT SCIENCE
• ISSN/ISSBN: 0025-1909
• DOI: 10.1287/mnsc.2021.4243
• 发表日期: 2022
• 页码: 6552-6571
• 关键词: R&D investments; drug development; product shocks; M&A; Biopharmaceutical Industry; FDA

摘要

How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using the Food and Drug Administration public health advisories as idiosyncratic negative shocks to approved drugs, we examine how drug makers react through investment decisions. Following these shocks, affected firms increase research and development (R&D) expenditures, driven by a higher likelihood of acquiring external innovations rather than developing novel projects internally. Such acquisition activities are concentrated in firms with weak research pipelines. We also find that competing developers move resources away fromthe affected therapeutic areas. Our results show how investments in specialized commercialization capital create path dependencies and alter the direction of R&D investments.